Ceftriaxone
- Product NDC
- 52584-148
- 11-digit product format
- 525840148
- Labeler code
- 52584
- Product ID
- 52584-148_d8eb4e2d-bd90-45cd-b6f3-94d4c22424b9
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Ceftriaxone Sodium
- Dosage form
- INJECTION, POWDER, FOR SOLUTION
- Route
- INTRAMUSCULAR; INTRAVENOUS
- Labeler
- General Injectables and Vaccines, Inc.
- Application
- ANDA203702
- Marketing category
- ANDA
- Marketing start
- 2019-05-17
- Marketing end
- 0000-00-00
- Substance
- CEFTRIAXONE SODIUM
- Active strength
- 1 g/1
- Pharmacologic classes
- Cephalosporin Antibacterial [EPC],Cephalosporins [CS]
- NDC exclude flag
- No
- Listing certified through
- 2021-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded product | product | 52584-148 | D | Discontinued by firm | 2026-08-17 | ||
| excluded package | package | 52584-148 | 52584-148-00 | D | Discontinued by firm | 2026-08-17 |
Observed NDC auxiliary status history#
This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
| Captured / source date | Dataset | Scope | Package NDC | Code | Status | Snapshot | Source SHA-256 |
|---|---|---|---|---|---|---|---|
| 2025-12-14 17:58 UTC · source 2025-12-05 | excluded product | product | D | Discontinued by firm | d630ba8d3edf… | 732f749b63fb… | |
| 2025-12-14 17:58 UTC · source 2025-12-05 | excluded package | package | 52584-148-00 | D | Discontinued by firm | d630ba8d3edf… | 732f749b63fb… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | excluded product | product | D | Discontinued by firm | f5e01cc5f278… | a2eaf40c39c3… | |
| 2025-08-27 00:01 UTC · source 2025-08-26 | excluded package | package | 52584-148-00 | D | Discontinued by firm | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded product | product | D | Discontinued by firm | 2ef7874e63bc… | 57b86245f4fa… | |
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded package | package | 52584-148-00 | D | Discontinued by firm | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded product | product | D | Discontinued by firm | a1b67e2a42f9… | c4cf2c586c0d… | |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded package | package | 52584-148-00 | D | Discontinued by firm | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded product | product | D | Discontinued by firm | cfe11265f3b6… | 090c488252e2… | |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded package | package | 52584-148-00 | D | Discontinued by firm | cfe11265f3b6… | 090c488252e2… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded product | product | D | Discontinued by firm | cdf11ea48f46… | ba0047e9e063… | |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded package | package | 52584-148-00 | D | Discontinued by firm | cdf11ea48f46… | ba0047e9e063… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded product | product | D | Discontinued by firm | 302b2466d912… | e7b80fea0513… | |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded package | package | 52584-148-00 | D | Discontinued by firm | 302b2466d912… | e7b80fea0513… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded product | product | D | Discontinued by firm | ed331223b511… | 672a5bd82f5f… | |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded package | package | 52584-148-00 | D | Discontinued by firm | ed331223b511… | 672a5bd82f5f… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded product | product | D | Discontinued by firm | 0efc9e666f02… | f202fb6c5f17… | |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded package | package | 52584-148-00 | D | Discontinued by firm | 0efc9e666f02… | f202fb6c5f17… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded product | product | D | Discontinued by firm | ad56d346431e… | cc804d4bbf1e… | |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded package | package | 52584-148-00 | D | Discontinued by firm | ad56d346431e… | cc804d4bbf1e… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded product | product | D | Discontinued by firm | 367a005e9d99… | 383a685ebd0f… | |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded package | package | 52584-148-00 | D | Discontinued by firm | 367a005e9d99… | 383a685ebd0f… |
| 2024-07-10 04:00 UTC · source 2024-07-09 | excluded product | product | D | Discontinued by firm | 557ba5c1ecfa… | 9c80585c8c6e… | |
| 2024-07-10 04:00 UTC · source 2024-07-09 | excluded package | package | 52584-148-00 | D | Discontinued by firm | 557ba5c1ecfa… | 9c80585c8c6e… |
| 2022-08-30 03:57 UTC · source 2022-08-29 | excluded product | product | I | Inactivated by FDA | fb8cb913e6d1… | eb8c232b6be0… | |
| 2022-08-30 03:57 UTC · source 2022-08-29 | excluded package | package | 52584-148-00 | I | Inactivated by FDA | fb8cb913e6d1… | eb8c232b6be0… |
| 2022-04-09 23:13 UTC · source 2022-04-08 | excluded product | product | I | Inactivated by FDA | 86f5da6cb304… | a595104c45d7… | |
| 2022-04-09 23:13 UTC · source 2022-04-08 | excluded package | package | 52584-148-00 | I | Inactivated by FDA | 86f5da6cb304… | a595104c45d7… |
| 2022-04-04 05:40 UTC · source 2022-04-01 | excluded product | product | I | Inactivated by FDA | bd6a592717d7… | 303034d00443… | |
| 2022-04-04 05:40 UTC · source 2022-04-01 | excluded package | package | 52584-148-00 | I | Inactivated by FDA | bd6a592717d7… | 303034d00443… |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203702-001 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | |
| A203702-002 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | |
| A203702-003 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | |
| A203702-004 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A203702-001 | AP |
| A203702-002 | AP |
| A203702-003 | AP |
| A203702-004 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | AP | 2016-06-29 | d8e5a09893c0… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A203702-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A203702-002 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A203702-003 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A203702-004 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-001 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-002 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-003 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A203702-004 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-001 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-002 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-003 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203702-004 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-001 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-002 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-003 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A203702-004 | AP | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-001 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-002 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-003 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203702-004 | AP | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-001 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-002 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-003 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203702-004 | AP | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-001 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-002 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-003 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203702-004 | AP | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-001 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-002 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-003 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203702-004 | AP | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-001 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-002 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-003 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203702-004 | AP | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-001 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-002 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-003 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203702-004 | AP | 1 | d8e5a09893c0… |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 52584-148-00 | 2022-12-14 | C162847 | 48780-1 | d6a99b39-a561-a426-e053-dadaa90af4c2 | Ceftriaxone for Injection, USP |
| 52584-148-00 | 2022-01-28 | C162847 | 48780-1 | d6a99b39-a561-a426-e053-dadaa90af4c2 | Ceftriaxone for Injection, USP |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sportpharm LLC | 85ce4f8b-77e0-48bf-9f57-93f1478befa2 | 2026-04-24 | Warnings, Adverse reactions | 203702 ANDA203702 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sportpharm LLC | 9a937e47-8c36-4656-83e1-b3c18ed9bac3 | 2026-04-24 | Warnings, Adverse reactions | 203702 ANDA203702 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Qilu Pharmaceutical Co., Ltd. | 4cdf0743-c62b-4969-b9c9-4c6400644f6c | 2026-02-04 | Warnings, Adverse reactions | 203702 ANDA203702 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | 53415af6-4072-4339-83e2-d870ae02a0e2 | 2024-08-20 | Warnings, Adverse reactions | 203702 ANDA203702 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | 790279d4-2456-4091-abec-960b78885432 | 2024-02-01 | Warnings, Adverse reactions | 203702 ANDA203702 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Asclemed USA, Inc. | f01cf0e5-caaf-4759-ba21-50f3aceff523 | 2023-09-02 | Warnings, Adverse reactions | 203702 ANDA203702 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Apotex Corp. | 5116231f-82d1-44be-b08e-560c9a50e5c5 | 2023-08-31 | Warnings, Adverse reactions | 203702 ANDA203702 |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | 42ba7a9d-7d2b-4eac-af59-897151a8c924 | 2022-05-02 | Warnings, Adverse reactions | 203702 ANDA203702 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 52584-148-00 | 52584014800 | 1 VIAL, SINGLE-USE in 1 BAG (52584-148-00) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-USE | 2019-05-17 | 0000-00-00 | No | No | Current |